Table 3 Participant disposition

From: Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants

 

Sanofi B.1.351

Pfizer BNT162b2

Sanofi D614

ITT # Participants

78

80

84

Non-Naïve at any timepoint

23

28

22

Non-Naïve between D28-M3(a)

11 (14.10%)

19 (23.75%)

12 (14.29%)

Covid infection cases D28-M3(b)

6 (7.69%)

11 (13.75%)

6 (7.14%)

Infected (a + b)

17 (21.79%)

30 (37.50%)

18 (21.43%)

  1. ITT intent to treat, D day, M month.
  2. aA participant anti-NP positive at Month 3 was considered as non-naïve in the D28-M3 time window unless participant had Covid before D28 (re-infection not considered).
  3. bA participant reporting Covid infection and testing positive with at least one diagnostic test.
Back to article page